Cervicovaginal Safety of the Formulated, Biguanide-Based Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitor NB325 in a Murine Model

Figure 5

Application of gel only (placebo) causes no damage to the cervicovaginal epithelium. Mice were exposed to the HEC-based formulation placebo and sacrificed after application for 10 min, 2 h, 4 h, or 8 h. Vaginal (a) and cervical epithelial tissues (b) were subsequently isolated and analyzed for damage. Representative micrograph fields from the 2 h exposure are shown. Images are representative of three mice per exposure duration.